another one about MS - interesting because it is about what is going wrong with NK-cells in MS. Researchers are calling it a milestone discovery.
German researchers have found that NK cells in the case of MS lose control over effector T-cells. These are the cells that are activated in the body in an immune response, in order to eliminate infected cells, and they are supposed to listen to the cues they get from NK cells. But according to this study, these T-cells stop doing what the NK cells tell them to do, and go haywire, crossing the blood brain barrier, wreaking havoc on the patients body (aka killing random healthy cells).
Researchers found this can be treated by blocking interleukin2 receptors with Dacluzimab, which has already been through an extensive clinical trial and has been approved by EMA (= European FDA) for treatment of MS patients last month.
full paper: http://www.ncbi.nlm.nih.gov/pubmed/27162345
German researchers have found that NK cells in the case of MS lose control over effector T-cells. These are the cells that are activated in the body in an immune response, in order to eliminate infected cells, and they are supposed to listen to the cues they get from NK cells. But according to this study, these T-cells stop doing what the NK cells tell them to do, and go haywire, crossing the blood brain barrier, wreaking havoc on the patients body (aka killing random healthy cells).
Researchers found this can be treated by blocking interleukin2 receptors with Dacluzimab, which has already been through an extensive clinical trial and has been approved by EMA (= European FDA) for treatment of MS patients last month.
full paper: http://www.ncbi.nlm.nih.gov/pubmed/27162345
![ME/CFS lecture | Dr Nancy Klimas | 2011 [Chronic Fatigue Syndrome / SEID / New Zealand] - YouTube](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
